Latest Healthcare News

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

HeraMED has secured a pilot agreement with Lee Health, a leading US non-profit health system, to trial its HeraCARE digital maternity platform, aiming to transform prenatal and postpartum care through remote monitoring and virtual engagement.

EMVision Medical Devices has begun a pivotal aeromedical study with the Royal Flying Doctor Service to test its portable First Responder brain scanner in remote emergency settings. The trial aims to validate device usability and workflow integration ahead of commercial rollout.

Ryman Healthcare reported a 13% revenue increase to NZD 413.8 million for H1 2025, yet swung to a significant net loss of NZD 45.2 million and suspended dividends, raising questions about its financial trajectory.

Ryman Healthcare reports a significant financial turnaround with its first positive free cash flow in over ten years, alongside upgraded sales and cost-saving targets for FY26 and completion of a major NZD 2 billion refinancing.

Ryman Healthcare has reported its first positive free cash flow in over a decade, driven by cost reductions and stronger sales momentum, while upgrading its sales guidance for FY26.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.